Oral contraceptive steroids as promoters of hepatocarcinogenesis in female Sprague-Dawley rats

James D Yager, R. Yager

Research output: Contribution to journalArticle

Abstract

A number of reports have described the occurrence of liver cell adenomas in women using oral contraceptives. Circumstantial evidence derived from human and early experimental animal data, together with the recent report of Taper [Cancer (Phila.). 42: 462-467, 1978], suggests that oral contraceptive steroids may be liver tumor promoters. The objective of this study was to determine whether the feeding of two commonly used oral contraceptive steroids, mestranol and norethynodrel, can promote diethylinitrosamine (DEN)-initiated hepatocarcinogenesis. Female Sprague-Dawley rats were partially hepatectomized and intubated with either water or DEN (5 mg/kg body weight) 24 hr later. Twenty-four hr after carcinogen treatment, the animals were separated into seven groups (15 rats/group). The treatment groups were as follows: DEN → mestranol, DEN → norethynodrel, DEN → mestranol plus norethynodrel, DEN → 0.05% phenobarbital, DEN → basal diet, H2O → phenobarbital, and H2O → mestranol plus norethynodrel. Steroid consumption was mestranol = 0.02 to 0.03 mg/kg body weight/day and norethynodrel = 0.5 to 0.75 mg/kg/day. These doses are equivalent to 10 to 15 times the human dose. Five animals from each group were killed after 4 months and ten after 9 months. Histochemically detectable γ-glutamyl transpeptidase positive foci, together with hematoxylin and eosin-detectable lesions and γ-glutamyl transpeptidase enzyme activity were scored in each liver. At both kill times, DEN-initiated animals fed diets containing mestranol, mestranol plus norethynodrel and phenobarbital had significantly greater numbers of γ-glutamyl transpeptidase foci (p

Original languageEnglish (US)
Pages (from-to)3680-3685
Number of pages6
JournalCancer Research
Volume40
Issue number10
StatePublished - 1980
Externally publishedYes

Fingerprint

Mestranol
Norethynodrel
Oral Contraceptives
Sprague Dawley Rats
Steroids
gamma-Glutamyltransferase
Phenobarbital
Carcinogens
Body Weight
Liver Cell Adenoma
Diet
Liver
Hematoxylin
Eosine Yellowish-(YS)
Water
Enzymes
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Oral contraceptive steroids as promoters of hepatocarcinogenesis in female Sprague-Dawley rats. / Yager, James D; Yager, R.

In: Cancer Research, Vol. 40, No. 10, 1980, p. 3680-3685.

Research output: Contribution to journalArticle

@article{8c280b65ca71473b9da29d5424a6f5ca,
title = "Oral contraceptive steroids as promoters of hepatocarcinogenesis in female Sprague-Dawley rats",
abstract = "A number of reports have described the occurrence of liver cell adenomas in women using oral contraceptives. Circumstantial evidence derived from human and early experimental animal data, together with the recent report of Taper [Cancer (Phila.). 42: 462-467, 1978], suggests that oral contraceptive steroids may be liver tumor promoters. The objective of this study was to determine whether the feeding of two commonly used oral contraceptive steroids, mestranol and norethynodrel, can promote diethylinitrosamine (DEN)-initiated hepatocarcinogenesis. Female Sprague-Dawley rats were partially hepatectomized and intubated with either water or DEN (5 mg/kg body weight) 24 hr later. Twenty-four hr after carcinogen treatment, the animals were separated into seven groups (15 rats/group). The treatment groups were as follows: DEN → mestranol, DEN → norethynodrel, DEN → mestranol plus norethynodrel, DEN → 0.05{\%} phenobarbital, DEN → basal diet, H2O → phenobarbital, and H2O → mestranol plus norethynodrel. Steroid consumption was mestranol = 0.02 to 0.03 mg/kg body weight/day and norethynodrel = 0.5 to 0.75 mg/kg/day. These doses are equivalent to 10 to 15 times the human dose. Five animals from each group were killed after 4 months and ten after 9 months. Histochemically detectable γ-glutamyl transpeptidase positive foci, together with hematoxylin and eosin-detectable lesions and γ-glutamyl transpeptidase enzyme activity were scored in each liver. At both kill times, DEN-initiated animals fed diets containing mestranol, mestranol plus norethynodrel and phenobarbital had significantly greater numbers of γ-glutamyl transpeptidase foci (p",
author = "Yager, {James D} and R. Yager",
year = "1980",
language = "English (US)",
volume = "40",
pages = "3680--3685",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

TY - JOUR

T1 - Oral contraceptive steroids as promoters of hepatocarcinogenesis in female Sprague-Dawley rats

AU - Yager, James D

AU - Yager, R.

PY - 1980

Y1 - 1980

N2 - A number of reports have described the occurrence of liver cell adenomas in women using oral contraceptives. Circumstantial evidence derived from human and early experimental animal data, together with the recent report of Taper [Cancer (Phila.). 42: 462-467, 1978], suggests that oral contraceptive steroids may be liver tumor promoters. The objective of this study was to determine whether the feeding of two commonly used oral contraceptive steroids, mestranol and norethynodrel, can promote diethylinitrosamine (DEN)-initiated hepatocarcinogenesis. Female Sprague-Dawley rats were partially hepatectomized and intubated with either water or DEN (5 mg/kg body weight) 24 hr later. Twenty-four hr after carcinogen treatment, the animals were separated into seven groups (15 rats/group). The treatment groups were as follows: DEN → mestranol, DEN → norethynodrel, DEN → mestranol plus norethynodrel, DEN → 0.05% phenobarbital, DEN → basal diet, H2O → phenobarbital, and H2O → mestranol plus norethynodrel. Steroid consumption was mestranol = 0.02 to 0.03 mg/kg body weight/day and norethynodrel = 0.5 to 0.75 mg/kg/day. These doses are equivalent to 10 to 15 times the human dose. Five animals from each group were killed after 4 months and ten after 9 months. Histochemically detectable γ-glutamyl transpeptidase positive foci, together with hematoxylin and eosin-detectable lesions and γ-glutamyl transpeptidase enzyme activity were scored in each liver. At both kill times, DEN-initiated animals fed diets containing mestranol, mestranol plus norethynodrel and phenobarbital had significantly greater numbers of γ-glutamyl transpeptidase foci (p

AB - A number of reports have described the occurrence of liver cell adenomas in women using oral contraceptives. Circumstantial evidence derived from human and early experimental animal data, together with the recent report of Taper [Cancer (Phila.). 42: 462-467, 1978], suggests that oral contraceptive steroids may be liver tumor promoters. The objective of this study was to determine whether the feeding of two commonly used oral contraceptive steroids, mestranol and norethynodrel, can promote diethylinitrosamine (DEN)-initiated hepatocarcinogenesis. Female Sprague-Dawley rats were partially hepatectomized and intubated with either water or DEN (5 mg/kg body weight) 24 hr later. Twenty-four hr after carcinogen treatment, the animals were separated into seven groups (15 rats/group). The treatment groups were as follows: DEN → mestranol, DEN → norethynodrel, DEN → mestranol plus norethynodrel, DEN → 0.05% phenobarbital, DEN → basal diet, H2O → phenobarbital, and H2O → mestranol plus norethynodrel. Steroid consumption was mestranol = 0.02 to 0.03 mg/kg body weight/day and norethynodrel = 0.5 to 0.75 mg/kg/day. These doses are equivalent to 10 to 15 times the human dose. Five animals from each group were killed after 4 months and ten after 9 months. Histochemically detectable γ-glutamyl transpeptidase positive foci, together with hematoxylin and eosin-detectable lesions and γ-glutamyl transpeptidase enzyme activity were scored in each liver. At both kill times, DEN-initiated animals fed diets containing mestranol, mestranol plus norethynodrel and phenobarbital had significantly greater numbers of γ-glutamyl transpeptidase foci (p

UR - http://www.scopus.com/inward/record.url?scp=0018941624&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018941624&partnerID=8YFLogxK

M3 - Article

C2 - 6108158

AN - SCOPUS:0018941624

VL - 40

SP - 3680

EP - 3685

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 10

ER -